Effects of inhaling dihydroxyacetone from e-cigarettes on metabolism and cell function
Dihydroxyacetone exposure induces metabolic reprogramming and mitochondrial dysfunction
['FUNDING_R01'] · UNIVERSITY OF ALABAMA AT BIRMINGHAM · NIH-11213619
This study is looking at how breathing in a substance from e-cigarettes called dihydroxyacetone (DHA) might affect the lungs and heart, especially to see if it causes any harm over time, so we can better understand the health risks for people who use e-cigarettes.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF ALABAMA AT BIRMINGHAM (nih funded) |
| Locations | 1 site (BIRMINGHAM, UNITED STATES) |
| Trial ID | NIH-11213619 on ClinicalTrials.gov |
What this research studies
This research investigates how inhaling dihydroxyacetone (DHA), a compound produced during e-cigarette use, affects metabolic processes and cell function in the lungs and cardiovascular system. The study aims to understand the potential cellular and metabolic stress caused by both acute and chronic exposure to DHA. By examining the effects on pulmonary and cardiovascular cells, the researchers hope to identify biomarkers that indicate damage or dysfunction resulting from DHA inhalation. This work addresses a significant gap in current knowledge regarding the health impacts of e-cigarette use.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals who regularly use e-cigarettes and are exposed to dihydroxyacetone.
Not a fit: Patients who do not use e-cigarettes or are not exposed to dihydroxyacetone may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to a better understanding of the health risks associated with e-cigarette use and inform guidelines for safer practices.
How similar studies have performed: While there has been research on the effects of e-cigarette components, the specific investigation of DHA's impact on pulmonary and cardiovascular cells is novel and untested.
Where this research is happening
BIRMINGHAM, UNITED STATES
- UNIVERSITY OF ALABAMA AT BIRMINGHAM — BIRMINGHAM, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: GASSMAN, NATALIE ROSE — UNIVERSITY OF ALABAMA AT BIRMINGHAM
- Study coordinator: GASSMAN, NATALIE ROSE
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.